A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity.
Read moreA UK-based clean technology leader – Oxford PV – recently set a new world record for conversion efficiency in a perovskite solar technology. These highly efficient solar panels have been touted by many to be the next step in the future of photovoltaics.
Read more